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 1 INTRODUCTION 
“I remember one night at Muzdalifa, with nothing but the sky overhead I lay awake 
amid sleeping Muslim brothers and I learned that pilgrims from every land--every color, and 
class, and rank; high officials and the beggar alike--all snored in the same language” 1.  What 
this excerpt from the autobiography of Malcolm X describes is common knowledge; we all 
snore at one time or another. Apart from being considered a nuisance, snoring may also be a 
symptom of a more serious condition: obstructive sleep apnea (OSA). 
 
1.1 History of sleep registration and obstructive sleep apnea 
The fact that some people stop breathing during sleep has been known for ages.  
Several medical reports in particular describe OSA symptoms and severely affected patients. 
It is, however, only over the course of the last few decades that OSA has been recognized as 
a disease with potentially major complications. 
The first registration of brain activity during sleep, and thereby the first sleep 
registration, was made by the German psychiatrist Hans Berger in 1929 2. In 1965, sleep 
apnea was identified by Gastaut et al. as an association between breathing abnormalities, 
snoring and daytime sleepiness in patients during sleep3. The disease was defined in one of 
the early studies of Guilleminault after a consensus meeting in 1976 4. 
Prior to the introduction of microchips and computer technology there were few 
objective ways of measuring sleep and nocturnal breathing patterns. Accordingly, sleep 
medicine has evolved to be a specified medical field during the last 50 years. In 1970 the first 
sleep research center was established at Stanford University by William Dement. To gather 
more extensive information about sleep physiology a method called “polysomnography” 
(PSG) was introduced. In addition to the measurement of brain activity through EEG 
electrodes, several other measures, like respiration parameters, ECG, body position, pulse 
oximetry, eye movement and muscle tone were added.  Current definitions of sleep apnea 
and EEG arousals were published by the American Academy of Sleep Medicine in 2007 5, 
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and provide an evolution of the classic work by Rechtschaffen and Kales6. PSG is still the 
gold standard for sleep recordings, but it is expensive, complicated and requires an overnight 
stay in a hospital or sleep clinic. With the evolution of sleep recording equipment it is now 




1.2 Obstructive sleep apnea 
1.2.1 Definition 
OSA is a disorder characterized by repetitive upper airway obstruction resulting in 
nocturnal hypoxia and sleep fragmentation. OSA is a result of an obstruction of the upper 
airways during sleep caused by narrow airways and inadequate motor tone of the tongue 
and/or airway dilator muscles.  
According to the international classification of Sleep Disorders, second edition (ICSD-
2), OSA is categorized as a sleep related breathing disorder (SBD) 8. All SBD’s have in 
common the fact that breathing problems somehow affect sleep. Other sorts of SBD, 
comprising of central apneas, upper airway resistance syndrome and obesity hypoventilation 
syndrome (fomerly “Pickwick syndrome”) are not as frequent as OSA and will not be 
discussed in this thesis. 
Apnea-hypopnea index, or AHI, is an index used to assess the severity of sleep 
apnea based on the total number of complete cessations (apneas) and partial obstructions 
(hypopneas) of breathing occurring per hour of sleep. These pauses in breathing must last 
for 10 seconds or more and may be associated with a decrease in oxygenation of the blood. 
In general, the AHI can be used to classify the severity of disease (mild ≥5 to <15 
events/hour, moderate ≥15 to <30 events/hour, and severe ≥30 events/hour ) 5. Although AHI 
may define the number of breathing cessations, it does not say how long each breathing 
pause lasts, nor does it reflect the number and severity of oxygen desaturations. In clinical 
work it is therefore important both to take note of the AHI when deciding the severity of the 
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disease and to take into account other factors such as the length of apneas/hypopneas, the 
distribution of apneas vs hypopneas, oxygen saturation, respiratory effort related arousals 
and other signs of arousals. 
 
1.2.2 Diagnosis of OSA 
Diagnosis of OSA is based on the combination of characteristic clinical features (see 
subheading “Symptoms of OSA”) plus objective demonstration of abnormal breathing during 
sleep. A detailed clinical assessment forms an important part of the evaluation of patients 
suspected of having OSA. The gold standard for the diagnosis of OSA is polysomnography 
(PSG), and provides detailed information on sleep state and respiratory and gas exchange 
abnormalities in addition to a range of other variables. PSG studies generally involve a 
minimum of 7 channels of recordings that include EEG, electrooculogram (EOG), 
electromyogram (EMG), oronasal airflow, chest wall effort, body position, snore microphone, 
ECG, and oxyhemoglobin saturation 9. The duration of the diagnostic study should be at least 
6 hours, although this practice is not enforced in split-night studies, in which the initial part is 
devoted to diagnosis but the latter part involves the initiation of CPAP therapy, at which point 
an obvious case of OSA is evident. However, these studies are resource intensive in that 
they generally require the facilities of a full sleep laboratory and a trained technician.  
The large numbers of patients wishing to be assessed for possible OSA has focused 
attention on the role of home-based sleep studies. Some of the major advantages of such 
home-based studies are related to cost savings and efficacy, thereby reducing waiting lists 
and reducing treatment delay 10. Another is that patients remain in their familiar sleep 
environment. In Norway, increasing demand for sleep registrations generates long waiting 
lists and considerable delays in treatment.  
Sleep monitors are divided into different levels according to which channels they 
utilize and whether the test is performed in-laboratory or unattended. According to the 
American Academy of Sleep Medicine (formerly American Sleep Disorders Association) 
studies for sleep evaluation can be classified into four levels 9. This classification categorizes 
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various types of sleep monitors according to attendance and the number of physiologic 
channels measured: 
Level 1: Full attended in-laboratory polysomnography  
≥ 7 channels with sleep staging  
Level 2: Full unattended portable polysomnography  
≥ 7 channels with sleep staging  
Level 3: Portable, unattended sleep apnea monitors 
≥ 4 channels, no sleep staging  
Level 4: Limited unattended monitors  
1-3 channels, no sleep staging  
Note: Level 3 and Level 4 devices do not measure sleep time. 
 
 
1.2.3 Symptoms of OSA 
Nighttime symptoms 
Snoring is an important symptom of OSA given that it reflects the basic 
pathophysiology of the disorder. Snoring, as well as hypopneas and apneas are caused by a 
narrowing of the upper airways 11. Snoring is the most frequent symptom of OSAS, occurring 
in up to 95% of patients, but has poor predictive value because of the high prevalence of 
snoring without OSA in the general population 12. Concern by the bed partner about 
witnessed breathing pauses during sleep is a common reason for referral to a sleep clinic. 
Witnessed apneas is a good predictor of OSA, but says nothing about the severity 13. 
Choking or gasping during the night is another common symptom upon waking during an 
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obstructive apnea. Although it only lasts a few seconds it may be quite frightening for both 
patient and bed partner. 
Insomnia, and sleep maintenance insomnia in particular, is often recognized as a 
symptom of OSA 14;15. There are also several other nocturnal symptoms such as nocturia, 
enuresis, frequent arousals, excessive sweating and impotence 16. 
 
Daytime symptoms 
Excessive daytime sleepiness is a common complaint in OSA patients and is 
increasingly considered to be a significant health problem which can lead to accidents, 
psychosocial morbidity and poor quality of life 17. However, the subjective evaluation of 
excessive daytime sleepiness is complicated by the fact that patients may complain of 
fatigue, tiredness and lack of energy rather than sleepiness itself 18. Other daytime symptoms 
include increased appetite, memory impairment, personality changes, irritability, morning 
headache, anxiety and depression 19. 
 
1.2.4 Increasing prevalence of OSA in the general population 
OSA is a common disease, which is gradually becoming more widely recognized by 
the general public. The extent of undiagnosed OSA in the general population has been 
estimated to represent 5 % of adults 20, and at least 75 % of OSA patients remain 
undiagnosed 21. In their 1988 Wisconsin Sleep Cohort Study, Young et al. demonstrated 
sleep apnea, as diagnosed by PSG, to be a common disorder in the general, middle aged 
population, affecting approximately 24% of men and 9% of women (AHI ≥ 5 events/hour) 22. 
The prevalence of moderate to severe OSA (AHI ≥ 15 events/hour) was estimated to 4% in 
women and 9 % in men. The Wisconsin project repeats PSG every 4th year, with the last 
article published by Peppard et al. showing the prevalence of OSA to have increased 
markedly over the last two decades23. The current prevalence estimates of moderate to 
severe OSA (AHI ≥ 15 events/hour) are now 10% (95% confidence interval (CI): 7, 12) 
among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 
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2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women. 
This shows a substantial increase in OSA over the last 2 decades (relative increases of 
between 14% and 55% depending on the subgroup). The main explanation of this increase is 
the obesity epidemic, as obesity is a risk factor for developing OSA 24. 
A large Norwegian population based cohort study based on the Akershus Sleep 
Apnea Project (ASAP) was published in 2011 by Hrubos-Strøm et al. demonstrating a similar 
prevalence of sleep apnea in a middle aged (30-65 years) Norwegian population as was 
demonstrated in the United States some 20 years ago. The overall prevalence of OSA, AHI ≥ 
5 events/hour, in the ASAP was 16% and AHI ≥ 15 events/hour 8%25. Males had a greater 
prevalence than females with 21% vs 13 % had an AHI ≥ 5 events/hour and 11 % vs 6 % 
had an AHI ≥ 15 events/hour. 
 
1.2.5 Risk factors of OSA 
The three most important risk factors for OSA are obesity, male gender and older 
age. Obesity is an important pathogenic factor of sleep apnea 26;27. Approximately 70% of 
OSA patients are obese, and obesity is the only significant risk factor that is reversible 28. 
The prevalence of sleep apnea is greater in men than in women. Estimates show that 
the male/female ratio varies from 2:1 to 4:1 29. One explanation of the gender difference is 
hormonal differences resulting in different ways of storing adipose tissue, as males present 
with more central adiposity than females.  
It is believed that the strength and activity of the pharyngeal dilator musculature 
decreases with aging 30. Other risk factors include menopausal status, black racial status, 
alcohol, sedatives and smoking. 
Upper airway collapse is the key mechanism in OSA pathophysiology. This can both 
be due to negative pressure within the airway (as with inspiration), or to do with positive 
pressure outside the airways, as with local fat deposits or retrognathia. Patency is preserved 
by the action of the pharyngeal dilators and by the traction of the trachea. As an example,  
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tracheal traction  decreases in central obesity, making the upper airways more susceptible to 
collapse. 
 
1.2.6 Consequences and complications of OSA 
OSA can cause sleep fragmentation, sympathetic activation, metabolic dysregulation, 
endothelial dysfunction, systemic inflammation, oxidative stress, hypercoagulation and 
neurohumoral changes 31. These changes may lead to other conditions like diabetes 32, 
hypertension 33, heart failure 34, cardiovascular disease 35, cerebrovascular disease 36 and 
traffic accidents 37, which all are among the most frequent complications of OSA. 
An 18 year mortality follow-up was the basis of a population-based Wisconsin Sleep 
Cohort sample study (n = 1522) published in 2008 38. They found a significant high mortality 
risk with untreated OSA, independent of age, sex, BMI and symptoms of sleepiness. The 
adjusted hazard ratio (HR, 95% CI) for all-cause mortality with severe versus no SDB was 
3.8 (1.6,9.0) after excluding persons who had used CPAP treatment. The adjusted HR (95% 
CI) for cardiovascular mortality was 5.2 (1.4,19.2).  
An observational study by Marin et al. compared the long-term cardiovascular 
outcomes in male OSA patients with or without CPAP treatment 39. 264 healthy men, 377 
simple snorers, 403 people with untreated mild-moderate OSA, 235 people with untreated 
severe disease, and 372 people with OSA undergoing treatment with CPAP were included in 
the analysis. Patients with untreated severe disease had a higher incidence of fatal 
cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 
per 100 person-years) than untreated patients with mild-moderate disease (0.55, p=0.02 and 
0.89, p<0·0001), simple snorers (0.34, p=0.0006 and 0.58, p<0.0001), patients treated with 
CPAP (0.35, p=0.0008 and 0.64, p<0.0001), and healthy participants (0.3, p=0.0012 and 
0.45, p<0.0001). Multivariate analysis, adjusted for potential confounders, showed that 
untreated severe OSA significantly increased the risk of fatal (odds ratio 2.87, 95%CI 1.17–
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7.51) and non-fatal (3.17, 1.12–7.51) cardiovascular events compared with healthy 
participants. 
Most studies of the cardiovascular effects of OSA and CPAP use include male 
subjects only. A cohort study of 1116 women, median follow-up 72 months, with 
cardiovascular death as end-point was performed by Campos-Rodriguez et al 40. Women 
with an AHI less than 10 were the control group. Further AHI of 10 -29 events/hour was 
classified as mild to moderate OSA and AHI ≥ 30 events/hour as severe. Patients with OSA 
were classified as CPAP-treated (adherence ≥4 hours per day) or untreated (adherence <4 
hours per day or not prescribed). Compared with the control group, the fully adjusted hazard 
ratios for cardiovascular mortality were 3.50 (CI, 1.23 to 9.98) for the untreated, severe OSA 
group; 0.55 (CI, 0.17 to 1.74) for the CPAP-treated, severe OSA group; 1.60 (CI, 0.52 to 
4.90) for the untreated, mild to moderate OSA group; and 0.19 (CI, 0.02 to 1.67) for the 
CPAP-treated mild to moderate OSA group. 
In conclusion, several lines of epidemiological evidence indicate that OSA is 
associated with increased risk of cardiovascular disease. However, although a causal 
relationship is biologically plausible, no randomized controlled trial has evaluated the effect of 
any OSA treatment on cardiovascular mortality or morbidity. 
 
1.2.7 OSA and glucose intolerance (type 2 diabetes/prediabetes) 
The association between OSA and type 2 diabetes mellitus (T2DM) is now well 
documented 41;42, with estimates suggesting that up to 40% of people with OSA have 
T2DM43. Most studies have addressed the possible relationship between OSA and 
subsequent T2DM. A recent meta-analysis of six prospective cohort studies including a total 
of 5953 participants, with follow-up periods of 2.7-16 years and 332 incident cases of T2DM, 
showed that moderate to severe OSA was associated with a greater risk of incident T2DM 
(RR 1.63; 95% confidence interval (CI): 1.09-2.45) compared with the absence of OSA 44. 
Several mechanisms, including intermittent hypoxia, sleep fragmentation and immune 
activation may contribute to this causal pathway 45-47. During intermittent hypoxia, the 
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alternation between hypoxia and normoxia will resemble ischemia/perfusion events 48. During 
the hypoxic/ischemic phase, the cells adapt to a low oxygen environment. During the 
reoxygenation/reperfusion phase there is then a sudden increase of oxygen in the cells 
resulting in the production of reactive oxygen species 49. Increased oxidative stress is a 
widely accepted participant in the development and progression of T2DM and its 
complications 50;51.  
Only a few studies have addressed the possible reverse direction of causality, that 
T2DM might cause OSA. Studying 941 men, West et al. showed that patients with T2DM 
have a high prevalence (23%) of OSA 52. Although a cross-sectional study, the authors  
speculated that T2DM might be an independent risk factor of OSA. Further, diabetic 
autonomic neuropathy is one factor that might partly explain the increased prevalence of 
OSA in patients withT2DM53-55. 
The discovery of an association between OSA and T2DM made the International 
Diabetes Federation (IDF) change their guidelines to implement information about OSA. At 
the same time, they also called for more research into the association between OSA and 
T2DM. Finally, few previous studies have addressed the relationship between OSA and 
prediabetes 56-58.  
 
1.3 Obesity 
With obesity becoming an increasing problem worldwide so too has the prevalence of 
OSA increased. These two highly intercorrelated conditions are both significant challenges 
within our time. Findings from the majority of large, long-term epidemiological studies 
indicate that being overweight or obese is associated with increased mortality 59;60. The 
lifespan of severely obese individuals is decreased by an estimated 5 to 20 years depending 





1.3.1 Definition of obesity 
Obesity is a medical condition in which excess body fat has accumulated to the extent 
that it may impair health 62. The degree of obesity is often classified according to the body 
mass index (BMI – defined as the weight divided by the square of the height (kg/m2)). WHO’s 
definition of normal weight is a BMI of 18.5-24.9 kg/m2. Overweight is defined as a BMI ≥ 25 
kg/m2, with the subclassifications preobese (BMI 25.0 – 29.9), obese class I (30.0 – 34.9), 
obese class II (35.0 – 39.9) and obese class III (≥40). Morbid obesity is defined as BMI ≥ 40 
kg/m2 or BMI ≥ 35 kg/m2 with at least one obesity related comorbidity 63. 
 
1.3.2 Obesity prevalence trends 
Rises in BMI is a worldwide phenomenon, with there being few places where it is 
stable or decreasing. Between 1980 and 2008, age-standardised mean global BMI increased 
by 0.4–0.5 kg/m2 per decade in men and women, with substantial differences across regions 
and gender. As many as 1.46 billion people worldwide were estimated to be overweight in 
2008 64.  
According to the latest report from National Health and Nutrition Examination Study 
(NHANES) the prevalence of obesity among US adults was 35.5% for men and 35.8% for 
women. The prevalence of morbid obesity was higher in women (8.2%) than in men (4.4%) 
65. Data from the HUNT study (Helseundersøkelsen I Nord-Trøndelag) demonstrates that 
among men, the prevalence of obesity increased from 7.7% in HUNT1 (1984-86) to 22.1% in 
HUNT3 (2006-8), and in women from 13.3 to 23.1% 66.  
 
1.3.3 Obesity and OSA 
There is a strong relationship between OSA and obesity 67;68. Approximately 70 % of 
patients with OSA are obese, and sleep apnea is present in 40% of obese persons 69;70. In 
obesity grade III (BMI ≥ 40 kg/m2) the prevalence rates of OSA are considerably higher than 
in the general population (often reported to be in the range of 39% to 90%) and the severity 
of sleep apnea is generally greater than that found in leaner clinical populations 71;72. 
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Peppard et al. demonstrated that a 10% change in body weight was associated with a 
parallel change of approximately 30% in the AHI 72.  It is probable that OSA is worsened by 
obesity because of fat deposition at specific sites. Fat deposition in the tissues surrounding 
the upper airway appears to result in a smaller lumen and increased collapsibility of the 
upper airway, predisposing to apnea 73;74. Central obesity (large neck circumference and 
visceral obesity) increases the pressure on upper airways and reduces the tension and 
hence the compliance of the trachea, which again makes the obese patient more susceptible 
to OSA 28. The causal relationship between OSA and obesity is probably bidirectional. There 
is compelling evidence demonstrating that obesity predisposes a person to OSA and that 
losing weight results in OSA improvement, although some studies also suggest that OSA 
itself may cause weight gain. Newly diagnosed OSA subjects have difficulty losing weight 
and may be predisposed to excessive weight gain compared to similarly obese subjects free 
of OSA 75. Factors such as reduced activity levels and increased appetite may contribute to 
weight gain in OSA patients 27. 
The repeated nocturnal activation of the sympathetic nervous system associated with 
OSA might contribute to obesity through inhibition of leptin secretion 76. Leptin is primarily 
produced by adipocytes and its level in the blood is proportional to fat mass. Leptin 
suppresses appetite and affects energy expenditure 77. On the other hand, Ghrelin, which is 
primarily secreted by the stomach, conveys an appetite stimulating message to the 
hypothalamus 78. Others have demonstrated that OSA is associated with leptin resistance 
and high levels of both leptin and ghrelin, and short sleep duration is thought to be the main 
contributing factor 79;80. OSA is also associated with elevated levels of c-reactive protein 
(CRP) and pro-inflammatory cytokines 81-83. CRP has been identified as one of the major 
serum leptin-interacting proteins, and may be one of the main agents responsible for leptin 
resistance in OSA 84;85. OSA also stimulates the hypothalamic–pituitary–adrenal axis, 
resulting in excessive cortisol secretion 86. Exposure to excessive cortisol leads to weight 




1.3.4 Other complications of obesity 
Obesity has several serious health effects and is associated with both increased 
morbidity and mortality 87;88. Quality of life is also impaired in both OSA and obesity 89. 
Obesity is associated with several life-threatening complications and contributes to ischaemic 
heart disease, stroke and diseases linked to the metabolic syndrome, such as hypertension, 
the dyslipidaemias, nonalcoholic steatohepatitis and polycystic ovary syndrome 90. The risk 
for developing cancer is also increased, particularly for colorectal cancer, but also 
oesophageal, pancreatic, renal, endometrial, breast and gall bladder cancers 91;92. Other 
obesity related complaints such as back pain, degenerative diseases of the hips and knees 
and depression are common 93. Data from the 2010 Global Burden of Disease study show 
that the most prevalent risk factor for years of life lost in Norway is dietary risks (and as a 
consequence obesity), with smoking being in second place 94.  
 
1.4  Treatment 
1.4.1 Treatment of OSA 
 
As OSA treatment now has become readily available it is important to diagnose 
affected patients in order to relieve symptoms and prevent complications 38. The 
management of OSA was revolutionized with the introduction of continuous positive airway 
pressure (CPAP), first described in 1981 by Colin Sullivan and associates in Sidney, 
Australia95. As the machines became more user friendly, smaller and less noisy, CPAP was 
widely adopted by the end of the 1980s. Previously, the ultimate treatment for OSA was 
tracheostomy, which bypassed anatomical areas susceptible to collapse in the upper 
airways. Although an effective treatment form, tracheostomy is invasive and not without 
complications.  
Mandibular advancement devices are another treatment option for selected patients, 
and the effect has been well documented in mild and moderate OSA 96. Different kinds of 
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surgery are recommended in different patients, despite  the fact that the long term effect is 
controversial 97. Lifestyle changes with a focus on exercise, healthy diet and weight reduction 
are often recommended as a part of OSA treatment and as a complement to other 
treatments which prevent deterioration of the condition 98;99.  
Despite the close relationship between OSA and obesity, only a few published 
randomized controlled trials have assessed the effect of weight loss on OSA 100-102. 
Tuomilehto et al examined the effect of a very low calorie diet followed by lifestyle counseling 
for one year in overweight and obese patients with mild OSA100. The intervention group had a 
significantly lower odds of having OSA at follow-up than the control group; OR 0.24 (95% CI 
0.08,0.72). In the Sleep AHEAD study intensive lifestyle changes in overweight or obese 
patients with T2DM and mild to severe OSA were associated with a significant improvement 
in AHI 101. Finally, Johansson et al reported that a nine week very low energy diet in obese 
men with moderate to severe OSA improved OSA (particularly severe OSA) compared to a 
control group which adhered to their usual diet102.  
A meta-analysis performed by Ashrafian et al aimed to determine whether there was 
a greater AHI reduction in surgical compared to non-surgical weight loss studies103. However, 
because of the heterogeneity and quality of the available trials, the authors were unable to 
conclude whether there was a relative benefit on AHI from surgical methods or not.  
According to the available evidence weight reduction reduces AHI, but it is unknown 
how lifestyle modifications and bariatric surgery differ in terms of their ability to reduce OSA. 
 
1.4.2 Treatment of obesity 
To reduce weight there are two main principles that form the basis of all treatment; to 
reduce energy intake and to increase energy expenditure. A medical approach to achieving 
weight loss includes dietary modifications, physical activity, drugs and behavioural 
interventions. The surgical approach includes different types of bariatric surgery. As with 
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medical treatment, the long term (≥ 1 year) weight reduction is expected to be 5-20%, in 
contrast to surgical treatment which has a long term weight loss of around 30% 104-106.  
The cornerstones of obesity treatment are diet, exercise and behavior therapy; 
together referred to as lifestyle modification. Lifestyle modification is different from dieting, 
with dieting implying adherence to a particular programme for a set period of time. Lifestyle 
modifications, however, may be sustained over an entire life span if desired. The 
maintenance of weight reduction, regardless of the initial method of reducing weight, relies 
on lifelong lifestyle modifications. Bariatric surgery is basically an extreme means of helping 
patients to change their eating behavior. If the patients return to their old eating habits after 
bariatric surgery then they will regain weight. 
 
Dietary interventions 
Dietary interventions for obesity are designed to motivate the patient to consume 
fewer calories than he or she expends (a negative energy balance). Energy requirements 
vary by sex, weight and level of physical activity. The greater the energy deficit is the greater 
is the weight loss. According to the National Institute of Health’s 2000 publication “Practical 
Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults”, 
calorie restricted diets designed to create an energy deficit of 500-1000kcal/day may induce 
a weight loss of 0.5-1 kg during the first weeks 107, and 10-20 kg during the first year 108. If a 
larger weight loss is necessary, a low-calorie diet (LCD; 800-1200 kcal/day) or a very-low-
calorie diet (VLCD; < 800 kcal/day) may be appropriate for 3-12 weeks 109. 107 
 
Physical activity 
The benefits of physical activity include inducing calorie expenditure, sparing fat-free 
mass during weight loss and improving cardiovascular fitness. The greatest benefit of 
physical activity is that it facilitates the maintenance of weight loss 110.  Subjects who receive 
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diet plus exercise maintain greater weight losses 1 year after treatment than those who diet 
only 111.  
Isolated physical activity without weight loss may also have a positive effect on OSA 
112. Exercise leads to more muscles and less fat; the lower pharyngeal pressure from 
diminished fat deposits might decrease the severity of OSA. 
 
Behavior therapy 
Behavior therapy provides patients a set of principles and techniques to facilitate their 
adherence to the diet and activity goals described above. Common techniques include self-
monitoring (of food and activity), stimulus control, slow eating, cognitive restructuring, 
problem solving and relapse prevention 113.  
 
Surgical Interventions 
Bariatric surgery, the most intensive treatment for obesity, is appropriate for morbidly 
obese individuals who have failed to lose weight by other means 114. Several studies have 
also indicated that bariatric surgery is effective in the treatment of T2DM 115-117, although the 
supporting evidence is debatable 118. The number of bariatric surgery procedures have 
increased during the last decade in tandem with the increasing prevalence of obesity 119. 
Surgical intervention utilizes two different approaches to weight loss: reducing food intake by 
restricting gastric volume and malabsorbtive procedures, which reduce energy uptake by 
bypassing parts of the gastrointestinal tract. These two principals may be combined in the 
same surgical procedure. The first procedures were carried out in the 1950’s and they were 
purely malabsorptive. Serious complications mean that this procedure gave way to restrictive 
methods in the 1980’s and 90’s, again with their set of complications.  
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The gastric bypass procedure, combining malabsorption and restriction, is now the 
most common procedure in bariatric surgery. The procedure has been modified since its 
introduction in the 1960’s to its present form today 120. This is by far the most common 
bariatric procedure performed in Norway today and accounts for more than 90 % of all 
procedures 121. A Rou-en-Y gastric bypass first divides the stomach into a small upper pouch 
of about 30 ml and a much larger, lower “remnant” pouch. The small pouch is then 
anastomosed to a Roux-en-Y proximal jejunal segment (Figure 1). 
 
 
   
Figure 1. Roux-en-Y gastric bypass (Figure by K.Toverud 122). 
1.5 Summary of introduction 
Although the symptoms of OSA have been known for centuries, research on the 
illness spans only a few decades. The gold standard for diagnosing OSA is PSG, but with 
increasing prevalence in the general population there is a growing demand for more 
simplified and efficient methods of diagnosis. Several lines of evidence suggest that weight 
reduction in obese subjects reduces AHI, but the comparative effectiveness of intensive 
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lifestyle modification and bariatric surgery on the severity of OSA has not previously received 
attention. Finally, the association between OSA and T2DM is well documented, but the odds 
of OSA among severely obese subjects with prediabetes or T2DM compared to those with 
normal glucose tolerance has not been explored. 
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2 AIMS OF THE THESIS 
The specific aims of the studies in this thesis were 
1. to investigate whether treatment seeking grade III obese patients with type 2 diabetes  
or prediabetes have higher odds of obstructive sleep apnea than their counterparts 
with normal glucose tolerance. 
 
2. to assess whether Roux-en-Y gastric bypass would be more effective than intensive 
lifestyle intervention at reducing the prevalence and severity of obstructive sleep 
apnea in morbidly obese patients . 
 
3. to validate the diagnostic accuracy of a simple three channel (type IV monitor) sleep 




3 MATERIALS AND METHODS 
3.1 Overview of study designs  
The results in this thesis are based on cross sectional (paper I) and longitudinal data 
(paper II) from the one-year non-randomized controlled clinical MOBIL study (Morbid Obesity 
treatment, Bariatric versus Intensive Lifestyle intervention) and data from the validation study 
of the ApneaLink™ (paper III).  
 
Table 1 Study design, population and sample size 
Paper Study design Population Participants 
I Cross sectional study Treatment seeking 
subjects with obesity 
grade III 
137 
II Non-randomized controlled study Treatment seeking 
morbidly obese subjects 
59 Intensive Lifestyle Interve
74 Roux-en-Y Gastric Bypas
III Validation study Treatment seeking 




3.2 Participants and study design 
Participants in all three studies were referred to the Morbid Obesity Centre at Vestfold 
Hospital Trust, a regional tertiary care center in Health Region South East, Norway. The 
center is located in Tønsberg and serves around 1 million inhabitants in Southern Norway. It 
was established in 2004 and is today one of two tertiary health care centers treating morbidly 
obese in South-Eastern Norway. The main tasks of the center are to evaluate, assess and 
treat morbidly obese subjects, to conduct research in the field and to educate and support 
other health care centers treating obese patients 123. The intensive lifestyle intervention 
programme was carried out at Evjeklinikken, a center specializing in obesity treatment. The 
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participants in paper I had obesity grade III (BMI≥40 kg/m2) and the participants in the two 
other papers were all morbidly obese.  
 
3.2.1 Non-randomized clinical trial including cross sectional analysis of baseline data 
(Paper I and II) 
Papers I and II include treatment seeking morbidly patients who participated in the 
MOBIL study. A flowchart of the patients in the MOBIL study is presented in figure 2. The 
study aimed to compare the effects of bariatric surgery and intensive lifestyle intervention on 
various obesity related comorbidities 124-128. The sample size (80 % statistical power, α-level 
of 0.05 and equal distribution to the treatment groups) was calculated based on anticipated 
remission rates of OSA and T2DM 104. Given remission rates of OSA of 30 % in the surgery 
group and 10 % in the ILI group, at least 65 subjects with OSA were required.  
Patients (n=228) were pre-screened for participation in the study between December 
2005 and May 2006. The 181 patients who satisfied the criteria for bariatric surgery and 
wanted either gastric bypass surgery or intensive lifestyle intervention were referred to a 
screening examination. This baseline examination included sleep registration, an oral 
glucose tolerance test, 24-hour ambulatory blood pressure monitoring, pulmonary function 
tests, quality of life questionnaires and a structured dietary interview. A total of 146 patients 
were enrolled in the study with 66 patients in the intensive lifestyle intervention group and 80 
patients in the surgery group. The decision as to which treatment option to choose was 
based on a thorough assessment made by the multidisciplinary team (internist, dietitian, 
nurse, physiotherapist and surgeon). During the first visit the internist established a detailed 
medical history, checked previous diagnostic workups, performed a physical examination 
and briefly informed the patients of further investigations and treatment alternatives. At the 
second visit the doctor reiterated this message, providing complete information about the 
possible risks and benefits of an operation and encouraging the patients to incorporate their 
own values and preferences in the decision-making process. If no contraindication against 
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surgery existed, the patient and the physician together agreed upon the most appropriate 
choice of therapy; either surgical or conservative129. 
 
Patients in the surgical group completed a low calorie diet (800-900 kcal/day) three to 
six weeks prior to surgery with Roux-en-Y gastric bypass in order to reduce liver size. They 
were all encouraged to normalise eating behaviour and increase their physical activity. 
Patients in the intensive lifestyle intervention group were all referred to a rehabilitation 
center specializing in treating morbidly obese. All but four patients were at a center called 
Evjeklinikken, whilst the remaining patients stayed at places with similar programmes. The 
programme included four stays at the center (1 week at center, 10 w home, 4 w center, 12 w 
home, 1 w center, 23 w home, 1 w center). The programme included organized physical 
activity (3–4 h), psychosocially oriented interventions and individual consultations with a 
medical doctor, nutritionist, physiotherapist and trained nurse. Those leading the counseling 
interviews were trained in motivational interviewing, a client-centered counseling style that 
aims to invoke behavioral changes. The patients also took part in group sessions focusing on 
the emotional aspects of sedentary behavior and classroom lessons on topics related to 
nutrition, physical activity and co-morbidities. Patients were encouraged to follow the 
guidelines of the Norwegian National Council of Nutrition, which recommend that the daily 
intake of protein, fat, and carbohydrate, should account for 10–20%, <30%, and 50–60% of 
energy consumed respectively 104. When at home patients were encouraged to self-monitor 
their lifestyle habits (e.g. by keeping a physical activity diary and a food diary) and visit their 
general practitioner for weight monitoring. They were contacted by telephone every 2 weeks. 
The treatment aim was ≥10% weight loss. Vitamin supplements were not prescribed. 
 
Paper I is based on a cross sectional analysis of baseline data from the MOBIL study, 
but only participants with obesity grade III (BMI≥40 kg/m2) were included in the analysis 
(n=137). Since all patients in the MOBIL study were morbidly obese, patients in BMI range 
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35-40 kg/m2 had to be excluded because they, in accordance with the definition of morbid 
obesity, have an obesity related comorbidity. That means there was an overrepresentation of 
diabetic patients in this excluded group. Of the 181 patients screened for participation in the 
MOBIL-study [21], 35 patients were excluded due to a BMI < 40 kg/m² (n = 32) or a missing 
oral glucose tolerance test (n = 3). After the exclusion of an additional nine patients who 
failed to comply with sleep registrations, 137 extremely obese patients (101 females) were 
included in the present analysis. They had a mean (SD) age of 43 (11) years and BMI of 47 
(6) kg/m2. 
 
Paper II is based on follow-up data from the MOBIL study (1-year). All patients were 
morbidly obese. Of the 146 patients enrolled in the study, 66 patients were included in the 
intensive lifestyle intervention group and 80 patients in the surgery group. After exclusion 
based on different causes  (see flowchart in figure 2), 59 patients completed the study in the 
intensive lifestyle intervention group and 74 in the surgery group. The patients in the surgery 
group were significantly younger and heavier than those in the lifestyle group: mean (SD) 





Figure 2. Flowchart of participants in the MOBIL study completing sleep registration. 
Modified from Hofsø et al 104. 
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3.2.2 Validation study (Paper III) 
Paper III is a validation study of the portable somnograph ApneaLink™ against a 
reference method (Embletta™). Consecutive treatment seeking morbidly obese adults were 
recruited between March 2009 and February 2011 from the Morbid Obesity Centre. The 
exclusion criteria were immobile patients and inability to equip oneself with the recording 
devices. A total of 114 consecutive morbidly obese patients were eligible for inclusion. After 
the exclusion of eight patients with BMI < 35 kg/m2, 106 patients were included in the sleep 
study. Except for one patient with too short an evaluation time (<3 hours), all study 
participants successfully undertook sleep registration with Embletta™ (reference method), 
leaving 105 subjects, 64% (n=67) females, eligible for analysis. The patients had a mean 
(SD) age of 44 (11) years and BMI of 44 (6) kg/m2. 
 
 
3.3 Clinical characteristics and definitions 
Standardised forms were used for recording demographic and clinical data. 
Anthropometric measures were taken with patients in an upright position wearing light 
clothing and no shoes. Height was measured using a wall mounted stadiometer to the 
nearest 0.5 cm. Weight was measured to the nearest 0.1 kg and circumferences to the 
nearest 1 cm. Waist circumference was measured at the midpoint between the lowest rib 
margin and the iliac crest. Hip circumference was measured at the level of the major 
trochanter and neck circumference was measured at a point just below the larynx and 
perpendicular to the long axis of the neck. After at least five minutes of rest, blood pressure 
was measured three times using a sphygmomanometer. The average of the second and 
third measurements was registered. 
All patients apart from patients with drug-treated T2DM underwent a standardised 
oral glucose tolerance test 130. The patients were categorised into three groups according to 
the criteria of the American Diabetes Association: NGT; fasting plasma glucose <5.6 mmol/L 
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and/or 2-hour plasma glucose <7.8 mmol/L, prediabetes; fasting plasma glucose 5.6 - 6.9 
mmol/L and/or 2-hour plasma glucose 7.8 - 11.0 mmol/l or T2DM; fasting plasma glucose ≥ 
7.0 mmol/L or 2-hour plasma glucose ≥ 11.1 mmol/L. In supplementary analyses patients 
with prediabetes or T2DM were categorised as having abnormal glucose tolerance. 
 
3.4 Sleep registration, device descriptions and definitions  
Portable monitors were used for somnography so that each patient could be 
monitored in their natural sleeping habitat with their everyday pre-bed rituals. To avoid inter-
rater variation all recordings were manually scored by the same person (Jan Magnus 
Fredheim). 
 
3.4.1  Embletta™ 
We used Embletta™, a type II portable nine channel somnograph, for sleep 
registrations in all papers 131. Portable sleep diagnostic systems like the Embletta™ have a 
high sensitivity and are considered reliable in the diagnosis of OSA as there are few false 
positive results compared to polysomnography131;132. Although a type II portable monitor, we 
did not utilize the EEG or the ECG option in our studies, so for practical purposes it 
functioned as a type III monitor. 
Patients received both written and oral instructions regarding Embletta™ equipment 
usage. Patients equipped themselves and registrations were manually scored the following 
day. Treatment was provided according to current guidelines133. Patients already using 
CPAP had a one week wash-out period prior to the sleep registration where they did not use 
the machine. 
An apnea event was defined as a 90% or more reduction in baseline nasal air flow 
lasting at least ten seconds. Hypopnea events were defined as a 50% - 90% decrease in 
pre-event nasal air flow lasting ≥ 10 seconds accompanied by at least a 3% drop in oxygen 
saturation and/or signs of awakening or increased stress. Both supine and non-supine values 
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of AHI were recorded given that these might have clinical implications. Oxygen desaturation 
index (ODI) was defined as the number of episodes with at least a 3% drop in oxygen 
saturation per hour. Oxygen saturation (SPO2) in terms of both mean and lowest value 
through the night were measured by the finger pulse oxymeter.  
OSA was addressed as both a continuous (AHI) and categorical variable (OSA; 
yes/no, if yes: mild, moderate, severe). Other outcome variables were resolution of OSA (AHI 
cut off 5) and improvement of moderate or severe OSA (AHI≥15) to mild or no OSA. OSA 
was categorized as mild (AHI 5-15 events/hour), moderate (AHI15-30 events/hour) or severe 
(AHI ≥30 events/hour). Scoring rules were in accordance with the 2007 American Academy 
of Sleep Medicine (AASM) manual for the scoring of sleep 5.  
 
3.4.2  ApneaLink™  
In paper III Embletta™ was used as the reference method when we validated 
ApneaLink™ with three channels. The ApneaLink™ is a type IV portable somnograph with 
three channels (nasal airflow, pulse and oxygen saturation). The recorder is worn around the 
chest and a nasal cannula and pulse oximetry is attached to it. The internal memory and 
battery allow approximately 10 hours of recording. Accompanying software analyzes the 
recording and presents the data in a one-page report. The AHI is calculated based on total 
study time. It is possible to manually score the data, but the automatic report was the basis of 
our investigations. In our analyzes we used the automatic scoring algorithm to explore 
whether a non-sleep specialist can trust the automatic report produced by the device. The 
default software settings were used. These defined an apnea as a reduction of nasal flow by 
at least 80% of baseline lasting ten seconds or more. Hypopneas were defined as a 
decrease in nasal flow by 50-80% of baseline for ≥ 10 seconds. The maximum possible 
duration of an apnea was 80 seconds and the maximum possible duration of a hypopnea 
was 100 seconds. If apneas or hypopneas lasted longer than this it was automatically 
interpreted by the software as an artifact. 
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3.5 Laboratory analyses (paper I) 
Blood sampling was performed either in a fasting state or during an oral glucose 
tolerance test (OGTT)134. Standard 75 gram OGTTs with blood samples taken before and 
120 minutes after ingestion of glucose were performed, with an additional sampling at 30 
minutes. All blood samples were taken at the Department of Clinical Chemistry at Vestfold 
Hospital Trust. Samples clotted at room temperature and serum was separated from cells 
within 30 minutes (OGTT) or 2 hours (fasting samples). Serum samples were stored at either 
-20°C (analyses performed at the Hormone Laboratory, Oslo University Hospital Aker) or -
80°C (analyses performed at the Endocrine Laboratory, Oslo University Hospital 
Rikshospitalet) or analysed the same day (analyses performed at the Department of Clinical 
Chemistry at Vestfold Hospital Trust). Spot morning urine samples were collected and 
analysed the same day. 
 
3.6 Statistics 
Data are given as either mean (SD) or proportions (%) unless stated otherwise. 
Skewed variables were transformed using natural logarithms before statistical analysis. 
Between group differences were assessed using independent samples t-test or analysis of 
variance (ANOVA) (continuous data) and Fisher’s exact test (categorical data).  
In paper II within-group comparisons were performed using paired samples t-test for 
continuous variables and McNemar test for dichotomized variables. Between-group 
differences in outcome variables were assessed using t-test, Fisher exact test, and multiple 
logistic regression analyses with predefined explanatory variables.  
Multiple logistic regression analyses with pre-defined explanatory variables and OSA 
(yes/no, cut off AHI=5) as the dependent variable were performed in paper I. We fitted one 
crude (unadjusted) logistic regression model and then stepwise three separate multiple 
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logistic regression models. The multiple logistic regression analysis was repeated in all 
models using AHI cut off 15. 
To address the issue of multicollinearity, we assessed the variance inflation factor 
(VIF) in the logistic regression models.  
In paper III Bland-Altman plots with corresponding 95% limits of agreement (LoA) 
were used to assess agreement between the reference instrument and the instrument to be 
validated (ApneaLink™), as well as agreement between the two nights of ApneaLink™ 
registrations. The traditional Bland Altman plot assumes that variance in the measurements 
is constant across the observed range. For data where the variance is proportional to the 
measured value the limits of agreement will have to be correspondingly wider for higher 
measurement values than for lower 135. We applied the log transform to the data for 
calculation of LoA, with back transformation to original scale for interpretation resulting in 
diagonal LoA lines. Sensitivity and specificity for diagnosing various categories of OSA 
(Embletta™ as reference instrument) were calculated for different AHI values from the Apnea 
Link-studies. Receiver operating characteristics curves (ROC-curves) with corresponding 
area under the curve (AUC) were constructed to evaluate the diagnostic accuracy and to 
illustrate the true positive rate (sensitivity) against the false positive rate (1-specificity) at 
various AHI cut off values (5, 15 and 30). 
Data were analyzed by the Statistical Package of the Social Science (SPSS) for 
Windows, version 16 and 17 (SPSS, Chicago, IL, USA) and R 3.0.1 136. 
 
3.7 Ethics 
3.7.1 Approvals  
The Morbid Obesity Biobank Registry has the approval of the regional ethics 
committee of the Southern Norway Regional Health Authority (reference number S-05175), 
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HN
4 SUMMARY OF RESULTS 
4.1  Paper I 
Type 2 diabetes and prediabetes are associated with obstructive sleep apnea in 
extremely obese subjects: A cross-sectional study 
A total of 42 (31 %) patients had mild OSA, 18 (13 %) moderate OSA, and 24 (18 %)  
severe OSA. Further, 39 (29 %) subjects had NGT, 58 (42 %) prediabetes and 40 (29 %) 
T2DM. Among the patients with NGT, 33 % had OSA, while 67 % of the patients with 
prediabetes and 78 % of the T2DM patients also had OSA.  
BMI did not differ significantly between the various glucose tolerance groups. In 
contrast, mean age increased with worsening glucose tolerance. 
 
Association between OSA and various measures of glucose tolerance  
In a crude, unadjusted logistic regression model (model 1) subjects with prediabetes 
and T2DM had approximately 4- and 7-fold increased odds of OSA compared with the 
normoglycemic group (table 2). The odds of OSA among patients with prediabetes and 
T2DM were attenuated after adjustment for gender, age, BMI, HOMA-IR and high sensitive 
CRP (models 2-4), but remained statistically significant.  
As an addition to model 4 we adjusted for smoking, alcohol consumption, OSA 
relevant medication (benzodiazepines, tricyclic antidepressants and antipsychotics) and 
hypertension (systolic and diastolic), with none of these significantly altering the OR of 
having OSA (data not shown). After replacing AHI cut off 5 (events/hour) with AHI cut off 15 
as the dependent variable in the model, glucose tolerance was not significantly associated 





Model  1 
OR (95 % CI) 
Model  2 
OR (95 % CI) 
Model  3 
OR (95 % CI) 
Model  4 
OR (95 % CI) 
Prediabetes 4.4 (1.9-10.6) a 3.3 (1.1-9.4) c 3.2 (1.0-10.1) c 4.0 (1.2-13.2) c 
Type 2-
diabetes 
6.9 (2.5-18.7) a 4.3 (1.3-14.7) c 4.3 (1.2-16.4) c 5.4 (1.3-21.5) c 
Gender  5.3 (1.7-17.1) b 5.0 (1.5-16.5) b 4.2 (1.2-14.4) c 
Age  1.15 (1.08-1.21) a 1.15 (1.08-1.22) a 1.15 (1.08-1.21) a 
BMI  1.05 (0.97-1.14)  1.05 (0.97-1.14)  1.08 (0.99-1.18)  
HOMA-IR   1.0 (0.8-1.3)  0.9 (0.7-1.3)  
hsCRP    0.9 (0.7-1.0)  
a p≤0.001         b p≤0.01   c p<0.05   
Table 2 Odds of obstructive sleep apnea (AHI cut off 5) in extremely obese subjects with 
type 2-diabetes or prediabetes 
Data are given as odds ratio (95 % CI) using multiple logistic regression analysis. 
 
 
4.2 Paper II  
Obstructive sleep apnea after weight loss: a clinical trial comparing gastric bypass 
and intensive lifestyle intervention 
At baseline 84 patients (63%) had OSA (32% mild, 13% moderate, and 18% severe). 
The prevalence of mild, moderate, and severe OSA did not differ significantly between 
treatment groups (p = 0.159). The RYGB patients were significantly heavier and younger 
than the ILI patients (table 3). 
Compared with baseline, the prevalence of OSA was significantly lower after 
treatment in both the ILI-group (46% vs 68%) and the RYGB-group (20% vs 60%). In 
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addition, a significant number of patients changed from an AHI ≥15 events/h (requiring 
CPAP) at baseline to AHI <15 (not requiring CPAP) at follow-up: 19 subjects (73%) in the 
RYGB group and 8 subjects (53%) in the ILI group, within-group difference, p < 0.001 and 
0.039, respectively, between-group difference p = 0.306. 
OSA severity among the 84 patients with OSA at baseline reduced in both groups, 
although significantly more in the RYGB group than in the ILI group (Table 3). AHI reduced 
significantly more in the RYGB than in the ILI group, mean between group difference (95% 
CI) 7.2 (4.4, 21.2) events/h, p = 0.003. BMI-change correlated significantly with the change in 
AHI, r = 0.273, p = 0.001.  








Lifestyle (n=40) Surgery (n=44) 
p-value*** 
 
Age (years) 51.3 (8.9) 46.5 (9.4)    
Gender % (male/female) 38/62 43/57    
Anthropometric 
measures      
BMI (kg/m²) 43.9 (5.3) 47.5 (5.6) -4.2 (-5.4, -2.9)* -14.0 (-15.1, -12.9)* <0.001 
Body weight (kg) 127.4 (19.6) 141.5 (20.5) -12.1 (-16.0, -8.3)* -42.0 (-45.7, -38.3)* <0.001 
Neck circumference 
(cm) 41.8 (4.4) 43.9 (3.7) -0.3 (-2.2, 1.6) -5.1 (-5.7, -4.5)* <0.001 
Sleep registration      
AHI (events/h) 21.8 (20.9) 29.3 (24.1) -8.8 (-14.2, -3.4)** -21.6 (-28.2, -15.0)* 0.003 
ODI (events/h) 19.9 (16.1) 30.2 (24.6) -5.6 (-10.2, -1.1)** -22.9 (-29.6, -16.1)* <0.001 
Snoring (% of night) 19.5 (21.5) 24.2 (23.2) -5.2 (-12.5, 2.1) -14.4 (-22.1, -6.7)* 0.085 
SpO² (%) 92.6 (3.4) 92.8 (2.5) 0.8 (-0.4, 1.9) 2.3 (1.6, 3.0)* 0.021 
Lowest O2 78.0 (8.2) 75.8 (9.4) 4.0 (1.3, 6.7)** 9.0 (6.2, 11.8)* 0.012 
Supine AHI 23.6 (22.3) 41.5 (31.4) -5.4 (-12.4, 1.6) -29.5 (-40.0, -19.0)* <0.001 
Non supine AHI 21.7 (23.9) 25.9 (28.3) -10.2 (-17.0, -3.3)** -22.6 (-30.3, -15.0)* 0.018 
 
*p < 0.001 
**=p-value < 0.05 
*** between-group difference 
Data are presented as number (%) or mean (SD or 95 % CI).  
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Table 3 - Sleep registration and anthropometric characteristics in 84 morbidly obese patients 
with OSA (AHI≥5), at baseline and 1-year follow up, according to treatment group; intensive 
lifestyle intervention or Roux-en-Y gastric bypass surgery. 
 
 
At follow-up, remission of OSA (AHI <5 events/h) was registered in 29 of 44 (66%) 
RYGB patients and 16 of 40 (40%) ILI patients, between group difference p = 0.028. Another 
5 (13%) ILI patients and 7 (16%) RYGB patients improved to a less severe level of OSA at 
follow-up (figure 4). A total of 3 patients in the ILI group and one in the RYGB group 
deteriorated from no OSA to mild OSA. One RYGB patient and two ILI patients with mild 
OSA deteriorated to moderate OSA, and one patient in the ILI group deteriorated from 
moderate to severe OSA. AHI was reduced, with 0.93 events/h per kg weight reduction in the 
ILI group and 0.52 in the RYGB group, mean between-group difference (95% CI) 0.41 (−0.6, 
1.4), p = 0.405.  
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Figure 4 – Percentage distribution of change in OSA category (none, mild, moderate or 
severe) of 84 morbidly obese OSA patients treated with either intensive lifestyle intervention 
(ILI, 40 patients) or Roux-en-Y gastric bypass surgery (RGB, 44 patients). 
 
 
Treatment choice was an independent predictor of the presence of OSA (AHI ≥5 
events/h) at one year after adjusting for age, gender and baseline AHI. The surgical patients 
had a 67% lower odds of OSA at one year (OR [95% CI] 0.33 [0.14, 0.81], p = 0.015). After 
adding BMI change to this model treatment group assignment was no longer significant: OR 
(95% CI) 1.31 (0.32, 5.35), p = 0.709. There was no significant interaction between gender 
and treatment group in this multivariate logistic regression model adjusted for age, gender, 
baseline AHI and BMI change.  
 
 
4.3 Paper III  
Validation of a portable monitor for the diagnosis of obstructive sleep apnea in 
morbidly obese patients 
We aimed to validate the diagnostic accuracy and night-to-night variability of a simple 
three channel (type IV monitor) sleep registration device, ApneaLink™ (AL) in a population of 
morbidly obese subjects. 
The patients (n=105) underwent two successive nights of recordings; the first night 
with the AL only, and the following night with both the reference instrument Embletta™™ (E), a 
type II portable somnograph with nine channels, and the AL.  
A total of 63 patients (60%) had OSA as diagnosed by the reference instrument (E). A 
total of 29 subjects had mild OSA, 12 subjects had moderate OSA and 22 severe OSA. Men 
had a significantly higher prevalence and severity of OSA than women.  
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The mean AHI, oxygen desaturation index (ODI) and peripheral oxygen saturation 
(pO2) did not differ significantly between the three measurements. 
Bland-Altman plot with diagonal limits of agreement (LoA) showed narrow LoA for 
small AHI values and overall the plot showed good agreement between the two methods. 
The mean difference between the measurements was close to zero indicating little 
systematic bias between the two apparatus. AL had a tendency to slightly overestimate AHI 
at smaller values.  
The Bland-Altman showed good agreement between AHI values for the two AL 
registrations and a mean difference between methods close to zero. 
The sensitivity and specificity of the AL were 93% and 71% at the AHI cut-off 5 
events/hour and 94% and 94% at the AHI cut-off 15, respectively. The night-to-night 
variability was low. 
The AL misclassified 12 non-OSA patients (E-AHI<5) to have OSA, all of whom were 
categorized as having mild OSA. Further, 4 OSA patients (E-AHI≥5) with E-AHI range 5.9-7.6 
were misclassified as non-OSA. All patients with severe OSA (AHI≥30) were identified by the 
AL. 
The diagnostic accuracy of AL was high at all levels of OSA (mild, moderate, severe, 




The main results of the papers included in this thesis support the following 
hypotheses: 1) T2DM and prediabetes are associated with OSA in extremely obese patients. 
2) Gastric bypass surgery is more effective at reducing the prevalence and severity of OSA 
than intensive lifestyle intervention, and this effect seems to be mediated through weight 
loss. 3) A simple three channel sleep registration device, ApneaLink™, has a high diagnostic 
acccuracy in terms of diagnosing OSA in treatment seeking morbidly obese patients.  
This section of the thesis will discuss methodological aspects, limitations, compare 
the results with other studies and state possible clinical implications of the findings as well as 
suggest topics for future research. 
 
5.1 Methodological considerations 
5.1.1 Study designs and statistics 
The different study designs of the 3 papers in this thesis (cross-sectional study, non-
randomized controlled clinical trial and validation study) all have their particular strengths and 
limitations as will be discussed below. Patients included in all three papers were recruited 
from the Morbid Obesity Centre, which is a tertiary care center at Vestfold Hospital Trust. 
Taking this into account, the possibility of a sampling bias cannot be excluded. Subjects not 
seeking medical advice for their morbid obesity and patients who themselves take the 
initiative of seeking private treatment alternatives might differ from our population in several 
respects. As our subjects are morbidly or extremely obese (grade III) the results of our 
findings are not directly applicable to less obese or to normal weight subjects. The study 
population in all three studies was largely Caucasian, and as such the findings might not be 






The prevalence of obesity related comorbidities among morbidly obese with BMI 
between 35 and 40 kg/m2 is higher than in the general population with corresponding BMI, as 
this is part of the diagnostic criteria. In paper I we analysed the occurence of OSA in morbidly 
obese patients with prediabetes and T2DM. To reduce the possible selection bias among the 
patients with BMI 35 – 39.9 kg/m2 (obesity grade II), among whom the prevalence of T2DM 
would be artificially high, only patients with obesity grade III (BMI ≥ 40 kg/m2) were included. 
Since this study had a cross- sectional design it cannot be used to verify any causal 
relationship between T2DM and OSA. Given the current understanding of the 
pathophysiology of both OSA and T2DM our results do, however, allow speculation as to 
how T2DM and prediabetes might increase the risk of OSA. 
One of the strengths of this study is the relatively high number of extremely obese subjects 
with a high prevalence of abnormal glucose tolerance and OSA.  Using the data we also 
made gender specific calculations as to the prevalence of OSA among various glucose 
categories. Females were divided into two groups given that there is a difference in OSA 
prevalence among pre- versus postmenopausal women. However, stratification of data 
generally weakens the power of statistical analyses. This might have affected our results, as 
in paper I where we found no statistically significant difference in OSA prevalence between 
the different glucose categories among morbidly obese men or postmenopausal women. 
This finding might represent a type-II error, but is on the other hand in agreement with results 
from the Sleep AHEAD study where OSA prevalence significantly increased with the 
worsening of glucose tolerance in premenopausal women but not in postmenopausal women 
101. Another example from paper I where stratification could have weakened the result might 
be the analyses of leptin. We found lower leptin levels among patients with OSA than among 
non-OSA patients, a finding that contrasts with most other studies 79;137. Males do in general 
have lower leptin levels than females, and as the male proportion of OSA patients was quite 
high, that might partly explain the finding. We could, however, not find a gender difference 
between patients with and without OSA, potentially undermining the above explanation. As 
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there were only seven males without OSA a type-II error might be an explanation for the non-





At the time of publication there were, to the best of our knowledge, no other 
prospective clinical trials comparing the effects of bariatric surgery and intensive lifestyle 
intervention on the severity or resolution of OSA. The study is based on follow-up data (1-
year) from the MOBIL study.  
The MOBIL study was a non-randomized pragmatic clinical trial. In this context 
pragmatic means “practical”. The study design may infer reduced internal validity compared 
to a randomized design. The lack of randomization might lead to treatment allocation bias in 
particular. Subjects choosing intensive lifestyle intervention before surgery might be more 
motivated to say physical activity and a healthier diet. The two intervention groups were also 
different in terms of weight and age; patients in the surgery group were younger and heavier. 
The lack of randomization was, in light of ethical and legal concerns, considered 
unethical104.Our center is a public health care provider, and according to national guidelines 
patients should be offered either conservative or surgical therapy in an obesity clinic based 
on the multidiciplinary team model129. Randomization to surgery would therefore be 
questioned if the patient both wanted and qualified for a lifestyle intervention programme and 
vice versa. To be able to carry out a study comparing the two treatment options we had to 
adapt the study to the clinical everyday, not vice versa. This is the main reason we chose a 
practical (pragmatic) approach as opposed to a randomized trial design. 
One limitation of the study is the lack of registration of patient CPAP-usage and 
physical activity levels. Sedative drug and alcohol intake, both of which affect the degree of 




This study was a cross-sectional validation and diagnostic accuracy study. We 
validated the diagnostic accuracy and night-to-night variability of a simple sleep registration 
device, ApneaLink™, in a population of morbidly obese subjects. One of the strengths of this 
study is the relatively high number of participants (n=105). The gold standard of sleep 
registration is polysomnography (PSG). PSG is not available at our hospital, hence we 
utilized our existing equipment, Embletta™, as the reference method. Type II and III monitors 
(as the Embletta™) are by far more common in use in Norway than type I monitors (PSG). 
The agreement between Embletta™ and PSG has been shown to be good in validation 
studies 131;132. We thus deemed it legitimate to use Embletta™ as the reference method in 
this validation study. 
 
 
5.1.2 Sleep registration and diagnostic criteria 
Any method of sleep registration demands some sort of intervention, thereby 
interfering with the natural sleep pattern. The gold standard method is polysomnography, 
where the patients are admitted and monitored over the course of an entire nights sleep. This 
method is, however, expensive, time consuming and removes the patient from his/her natural 
sleep environment. Since our sleep registration equipment lacked EEG, we were not able to 
determine sleep time and sleep stages. Our calculation of AHI is therefore not based on 
actual sleep time but rather time in bed. All patients filled out a mandatory sleep diary ahead 
of the night where their sleep was to be registered, enabling us to decide when the patient 
slept. The advantage of portable monitors such as Embletta™ is that they allow the patient to 
maintain their normal sleep environment and pre-bed rituals.  
In our studies we used only a limited number of the available Embletta™ channels, 
meaning in practical terms that it was comparable to a type III monitor, although originally 
being a type II monitor.  
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The advantages of ApneaLink™ and other portable monitors compared to PSG 
include the cost-effectiveness and the fact that more patients might be diagnosed early, 
leading to substantial economic savings through the prevention of morbidity, accidents and 
absenteeism/presenteeism 138. Compared to more elaborate equipment the AL is practical to 
use, easy to interpret and its size and simplicity helps facilitate a more natural sleep and 
usage by non-specialists. 
 
5.1.3 Epworth Sleepiness Scale 
To evaluate daytime sleepiness we used the Norwegian translation of the Epworth 
Sleepiness Scale (ESS). This Norwegian version was validated by Beiske et al in 2009 139. 
They found that the internal consistency reliability, as assessed with Cronbach’s alpha, was 
0.84 (n=154). Test–retest reliability for the eight ESS items ranged from weighted kappa of 
0.61 to 0.80 (n=50) for the total score. Intra Class Correlation was 0.81.  
ESS is a subjective measure of daytime sleepiness, with multiple sleep latency test 
(MSLT) being the objective means of measurement. This test is based on the principle that 
degrees of sleepiness can be measured in terms of how quickly one falls asleep (sleep 
latency) when given the opportunity to do so. The association between ESS and MSLT is, 
however, quite poor, with the two tests arguably evaluating different but complementary 
aspects of sleepiness 140. In our studies we used subjective daytime sleepiness as measured 
by ESS. 
 
5.2  General discussion on specific findings 
5.2.1 Obstructive sleep apnea and glucose intolerance 
Our main finding in paper I was that extremely obese patients with T2DM and 
prediabetes had higher odds of OSA compared with normal glucose tolerance subjects. This 
finding was statistically significant even after adjustment for age, gender, BMI, insulin 
resistance, inflammation, hypertension, smoking, alcohol consumption and medication. The 
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evidence relating OSA to T2DM was strong enough to convince the International Diabetes 
Foundation to publish a consensus statement in 2008 outlining the need to screen for OSA in  
diabetes clinics 41. Since the consensus statement there has been an increasing recognition 
that obstructive sleep apnea (OSA) is associated with incident T2DM. A recently published 
meta-analysis of available prospective cohort studies as of March 2012 confirms this. Six 
studies with a total of 5953 participants, with follow-up periods of 2.7–16 years and 332 
incident cases of T2DM showed that moderate-severe OSA was associated with a greater 
risk of T2DM (RR 1.63; 95% confidence interval (CI): 1.09–2.45), as compared with the 
absence of OSA. For subjects with mild OSA the pooled RR of developing T2DM was 1.22 
(95% CI: 0.91–1.63). These findings support the notion/hypothesis that OSA may lead to 
T2DM.  
As paper I is a cross-sectional study causality cannot be inferred. Nevertheless, it can 
be speculated that there might be a bidirectional causal relationship between OSA and 
T2DM. Previous cross-sectional studies examining the relationship between OSA and 
glucose metabolism have mainly focused on the prevalence of T2DM and impaired glucose 
metabolism among subjects with OSA compared to subjects without OSA. Few studies have 
addressed OSA among subjects with established T2DM. The reported prevalence rates of 
OSA in diabetic populations range from 23% to 86% 52;56;141;142.  
 
It is well known that immune activation and subsequent increase in the circulating 
concentration of pro-inflammatory cytokines are associated with both adipose tissue and 
T2DM 143;144. Both these factors may play a role in the pathogenesis of OSA. T2DM is thus a 
condition which produces general inflammation. The increased mucosal thickness in the 
upper airways, secondary to general inflammation caused by T2DM, may contribute to 
airway narrowing and promote collapse of upper airways. According to our hypothesis this is 
one of two pathways by which T2DM may lead to OSA. 
The second part of our theory is based on the fact that the patency of the upper 
airways is largely dependent upon a well functioning nerve (vagal nerve), neuromuscular 
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junction and muscle (pharyngeal dilators).  Patients with T2DM have increased risk of 
neuropathy in the autonomic nervous system as well as in the extremities 145. Impaired vagal 
activity due to diabetic autonomic neuropathy may lead to dysfunction of upper airway 
muscles and increased risk of OSA 55. This theory is supported by the fact that respiratory 
disturbances are more frequent during rapid eye movement (REM) sleep when the tone of 
the UA dilator muscles is reduced. The autonomic contribution to maintaining a patent airway 
is therefore substantial. Diabetic autonomic neuropathy is a common complication of T2DM, 
but many patients are not aware of it because of multi-organ involvement and insidious 
onset. Because of varying diagnostic criteria there are big differences in the prevalence 
estimates of diabetic autonomic neuropathy. A study by Bottini et al of non-obese adults with 
diabetic autonomic neuropathy and postural hypotension showed a frequency of obstructive 
sleep apnea-hypopnea >30 percent 54. In obese subjects, diabetic autonomic neuropathy is 
also associated with an increased risk of obstructive sleep apnea compared with other obese 
subjects with or without T2DM 55. To conclude, T2DM might increase the risk of developing 
OSA via two mechanisms; by inflammation and by impairment of the autonomic nervous 
system controlling the UA dilator muscles.  
 
 
5.2.2 Obstructive sleep apnea and weight reduction 
In paper II we conclude that gastric bypass surgery is more effective than intensive 
lifestyle intervention at reducing the prevalence and severity of OSA in morbidly obese. 
Obviously one could argue that there is a big difference in weight loss between the two 
groups; the surgery group lost around 30% of their body weight and the lifestyle group 
around 10%. After multivariate analyses adjusting for weight loss there was no difference 
between the two treatment groups, suggesting that weight loss mediated the beneficial 
effects of surgery. Just after submission of paper II, a randomized controlled trial comparing 
surgical versus conventional therapy for weight loss treatment of obstructive sleep apnea 
was published 146. The study included 60 obese patients with an AHI of 20 events/hour or 
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more. Patients were randomized to a conventional weight loss programme or to bariatric 
surgery (gastric banding). Follow up was at 2 years compared to our one-year follow up, and 
the surgical procedure was different from that undertaken in our study. The expected weight 
loss after gastric banding was less than after gastric bypass, with mean (SD) excess weight 
loss after 10 years of 69 ± 29% versus 46 ± 27%, respectively, p = 0 .03 147. The surgical 
group achieved a significantly greater mean weight loss than the conventional group. Despite 
major differences in weight loss between the two treatment groups in the JAMA article there 
was statistically no greater reduction in AHI in the favor of surgery. In our study we 
performed subanalyses of patients with AHI ≥ 15 events/hour at baseline. As in the article by 
Dixon et al, we did not find any difference between this subgroup and treatment groups s 
improving their AHI to < 15 events/hour at follow-up. Still, we cannot rule out this being a 
type-II error – a failure to prove a difference between groups due to low number of study 
subjects.  
In a large randomized controlled trial study of the effects of weight loss on OSA in 
obese subjects with T2DM (the Sleep AHEAD study), weight loss produced by intensive 
lifestyle intervention significantly improved OSA as measured by AHI101. The control group 
were assigned to 3 group sessions related to effective diabetes management. The intensive 
lifestyle intervention participants lost more weight at 1 year than did DSE participants (10.8 
kg vs 0.6 kg; P < .00l). At 1 year, more than 3 times as many participants in the intensive 
lifestyle intervention group than in the control group had total remission of their OSA. Initial 
AHI and weight loss were the strongest predictors of changes in AHI at 1 year (P<.01). As in 
our study, the greatest improvement in OSA was observed in the participants who lost the 
most weight. 
One conclusion to draw from these two studies is that conventional means (i.e. 
lifestyle intervention) of intervention are also an effective means of reducing the severity of 




5.2.3 Obstructive sleep apnea and leptin 
In paper I we found lower leptin levels in OSA patients than in non-OSA patients, 
although this is an uncertain finding given that it might be the result of a type-II error. Leptin 
is a hormone that contributes to satiety perception and is known to decrease with sleep 
restriction 80. There is, however, a difference between sole sleep restriction and sleep 
disrupted by OSA. Studies of patients with OSA and similarly obese controls show that those 
with OSA had gained weight in the year preceding the diagnosis and had higher leptin levels 
than expected based on their percentage body fat 148;149, suggesting that OSA is associated 
with greater resistance to the weight-reducing effect of leptin and not obesity alone. This 
explains the typical high leptin levels in OSA patients and the coexisting leptin resistance. 
There are several intervention studies demonstrating a decrease in leptin levels in patients 
treated with CPAP 150-152. 
 
 
5.2.4 ApneaLink™ as a diagnostic tool 
A 2007 portable monitoring task force report was published in AASM’s own journal, 
Journal of Clinical Sleep Medicine, exploring the role of portable monitors in sleep 
diagnostics153. They concluded that portable monitors may be used as an alternative to PSG 
for the diagnosis of OSA in patients with a high pretest probability of moderate to severe 
OSA on the condition that it is used in conjugation with a comprehensive sleep evaluation. 
Patients in our population had a high pretest probability of moderate to severe OSA. The task 
force did not recommend type IV monitors such as the monitor we validated. In our 
population of morbidly obese the agreement between the reference method and 
ApneaLink™ was good. The sensitivity and specificity of the instrument were 93% and 71% 
at the AHI cut-off 5 events/hour and 94% and 94% at the AHI cut-off 15. In Norway, waiting 
lists for sleep registrations are generally long and few places offer PSG. In a clinical setting, 
our results indicate that monitors like the ApneaLink™ are safe to use as a diagnostic tool in 
morbidly obese subjects with suspected OSA. In accordance with the 2007 task force, this 
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tool should not be used in subgroups with significant comorbidities such as moderate to 
severe pulmonary disease, neuromuscular disease and congestive heart failure. Morbidly 
obese with massive central obesity must also be evaluated for obesity hypoventilation 
syndrome, where suspicion of this should lead to an examination of an arterial blood analysis 
to discover hypercapnia154. In cases of doubt, where clinical signs of OSA are prominent 
despite an AHI<5 events/hour, the recording might be repeated or more elaborate 
somnographs might be used. In most cases a patient diagnosed with OSA is treated with 
CPAP. A modern CPAP delivers sufficient data to evaluate whether a patient needs a CPAP 
(because he has no OSA) or a different positive pressure device like a VPAP (in cases of 
e.g. central apneas or Cheyne-Stokes respiration). Being able to bypass the more elaborate 
sleep registration methods for some patient groups might lower costs and reduce waiting 
lists. 
Our finding that the AL had a high diagnostic sensitivity in terms of the identification of 
subjects with OSA (AHI ≥ 5) is in accordance with previous validation studies of normal 
weight to overweight populations 155;156 and adolescents 157.  Importantly, we report a 
somewhat higher specificity than previous studies.  
The high sensitivity of the AL in the diagnosis of patients with moderate to severe 
OSA is in accordance with previous studies 155;158;159. The specificity regarding the diagnosis 
of moderate or severe OSA was, however, higher in our study compared to those reported 
by others, and the predictive value of a positive test was higher or equal to others. In 
addition, our validation study of AL with three channels (airflow, oximetry and pulse) showed 
better sensitivity, specificity and positive predictive value than previous studies of moderately 
obese subjects where AL had only one channel 160;161. 
The mean difference between the two ApneaLink™ recordings was close to zero, 
indicating a low night to night variability. A classic first night effect (FNE) is characterized by 
increased sleep onset latency, increased REM latency, a lower percentage of REM stage 
sleep and lower sleep efficiency as measured by polysomnography (PSG). The FNE typically 
leads to a lower AHI the first night compared to AHI measured the second night 162. FNE is a 
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phenomena described when PSG is performed in-hospital, where  environmental change 
(hospital bed versus own bed) and elaborate equipment affects sleep, particularly on the first 
night of repeated measures. Despite two consecutive nights of recordings we did not identify 
any first night effect (FNE). This is in accordance with other studies suggesting there is no 
significant FNE in portable sleep monitoring, although these studies are relatively few 163;164. 
The largest study of the night to night variability of home sleep testing by Stepnowsky 
examined the AHI in a retrospective comparison of 3 sequential nights in 1091 patients and 
found that 10 % were misclassified on night 1 relative to the highest AHI level165. 
 
5.3 Clinical implications 
We showed that both prediabetes and T2DM are associated with OSA in extremely 
obese subjects. In accordance with the recommendations from the International Diabetes 
Federation (IDF) all subjects with T2DM should be screened for OSA. Our results, if verified 
by others, suggest that it might also be appropriate to screen severely obese subjects with 
prediabetes for OSA. 
 
Gastric bypass surgery was more effective than intensive lifestyle intervention at 
reducing the prevalence and severity of OSA in a population of treatment seeking morbidly 
obese patients, and the beneficial effect of surgery seemed to be mediated by weight loss. 
Weight reduction using any method should have a high priority in the treatment of obstructive 
sleep apnea in morbidly obese patients. 
 
The simple three channel sleep registration device ApneaLink™ has a high diagnostic 
accuracy in diagnosing OSA in morbidly obese treatment seeking patients. Accordingly, this 
and similar instruments might help non-specialists to diagnose OSA in morbidly obese 
patients, and, importantly, help non-specialists to refer patients who need specific treatment 




5.4 Topics for future research 
In paper I we hypothesized that T2DM might cause OSA through at least two different 
pathways. This is yet to be confirmed by other studies, and is a potential research avenue. 
The association between prediabetes and OSA needs verification and further study.  
There are very few prospective studies comparing lifestyle intervention weight loss 
and bariatric surgery weight loss, and we would encourage such studies in the future in order 
to explore differences between surgical and non-surgical weight loss methods. 
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6 CONCLUSIONS  
In paper I we showed that prediabetes and T2DM are associated with OSA in 
extremely obese subjects. Our findings support the recommendations of the International 
Diabetes Federation (IDF), which suggest that subjects with T2DM should be screened for 
OSA. If the relationship between prediabetes and OSA is verified by others this may then 
indicate that obese subjects with prediabetes should also be screened for OSA. 
 
Gastric bypass surgery was more effective than intensive lifestyle intervention at 
reducing the prevalence and severity of OSA in a population of treatment seeking morbidly 
obese patients. The beneficial effect of surgical treatment seemed to be mediated by weight 
loss rather than RYGB per say. Intensive lifestyle intervention was also associated with 
significant improvements in OSA. Weight reduction should have a high priority in the 
treatment of obstructive sleep apnea in morbidly obese patients. 
 
The results from paper III indicate that a simple three channel sleep registration 
device (ApneaLink™) has a high diagnostic accuracy in terms of the diagnosis of OSA in 
treatment seeking morbidly obese patients. Accordingly, this and similar instruments might 
help non-specialists to diagnose OSA in morbidly obese patients, and, importantly, help non-
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Type 2 diabetes and pre-diabetes are associated
with obstructive sleep apnea in extremely obese
subjects: A cross-sectional study
Jan Magnus Fredheim1,2*, Jan Rollheim1, Torbjørn Omland3, Dag Hofsø1, Jo Røislien1,4, Kristian Vegsgaard2 and
Jøran Hjelmesæth1
Abstract
Background: Obstructive sleep apnea (OSA) is a common yet underdiagnosed condition. The aim of our study is
to test whether prediabetes and type 2 diabetes are associated with obstructive sleep apnea (OSA) in extremely
obese (BMI ≥ 40 kg/m2) subjects.
Methods: One hundred and thirty seven consecutive extremely obese patients (99 females) from a controlled
clinical trial [MOBIL-study (Morbid Obesity treatment, Bariatric surgery versus Intensive Lifestyle intervention Study)
(ClinicalTrials.gov number NCT00273104)] underwent somnography with Embletta® and a 2-hour oral glucose
tolerance test (OGTT). OSA was defined by an apnea-hypopnea index (AHI) ≥ 5 events/hour. Patients were
categorized into three groups according to criteria from the American Diabetes Association: normal glucose
tolerance, pre-diabetes and type 2 diabetes. Multiple logistic regression analysis was used to identify possible
determinants of OSA.
Results: The patients had a mean (SD) age of 43 (11) years and a body mass index (BMI) of 46.9 (5.7) kg/m2. Males
had significantly higher AHI than females, 29 (25) vs 12 (17) events/hour, p < 0.001. OSA was observed in 81% of
men and in 55% of women, p = 0.008. Twenty-nine percent of subjects had normal glucose tolerance, 42% had
pre-diabetes and 29% had type 2 diabetes. Among the patients with normal glucose tolerance 33% had OSA,
while 67% of the pre-diabetic patients and 78% of the type 2 diabetic patients had OSA, p < 0.001. After adjusting
for age, gender, BMI, high sensitive CRP and HOMA-IR, both pre-diabetes and type 2 diabetes were still associated
with OSA, odds ratios 3.18 (95% CI 1.00, 10.07), p = 0.049 and 4.17 (1.09, 15.88), p = 0.036, respectively. Mean serum
leptin was significantly lower in the OSA than in the non-OSA group, while other measures of inflammation did
not differ significantly between groups.
Conclusions: Type 2 diabetes and pre-diabetes are associated with OSA in extremely obese subjects.
Trial registration: MOBIL-study (Morbid Obesity treatment, Bariatric surgery versus Intensive Lifestyle intervention
Study) (ClinicalTrials.gov number NCT00273104)
Keywords: Obstructive sleep apnea, type 2 diabetes, prediabetes, oral glucose tolerance test, inflammation
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Introduction
Obstructive sleep apnea (OSA) is an under-diagnosed
yet common disease [1] which is associated with
increased incidence of cardiovascular disease and sub-
stantially increased risk of death [2,3]. There is a strong
relationship between OSA and obesity [4,5], indeed,
approximately 70% of patients with OSA are obese [6].
Obesity related subcutaneous and periluminal fat depos-
its may alter compliance of upper airway walls and nar-
row the luminal area, thus increasing the likelihood of
airway collapse when exposed to the intraluminal nega-
tive pressure caused by inspiration [5].
OSA is also associated with increased risk of type 2 dia-
betes (T2DM) [7,8]. Several mechanisms, including inter-
mittent hypoxia, sleep fragmentation and immune
activation may contribute to this association [8-11]. Both
adipose tissue and diabetes are associated with immune
activation and subsequent increase in the circulating con-
centration of pro-inflammatory cytokines [12,13], which
in turn may play a role in the pathogenesis of OSA.
All dilator muscles of the upper airways are innervated
by the vagal nerve, with patency of the upper airway
during sleep depending on well functioning nerve, neu-
romuscular junction and muscle. Diabetes increases the
risk of neuropathy in the autonomic nervous system as
well as in the extremities [14]. Impaired vagal activity
may lead to dysfunction of upper airway muscles and
increased risk of OSA [15].
Visceral obesity, high insulin levels and insulin resis-
tance have been associated with increased risk of OSA
[16,17]. Some studies have shown a high prevalence of
T2DM and pre-diabetes (preDM) in obese subjects with
OSA [17-20], indicating that OSA may cause glucose
intolerance [17].
We aimed to investigate whether extremely obese sub-
jects with T2DM and preDM have higher odds of OSA
than their counterparts with normal glucose tolerance.
Methods
Study design
This is a pre-defined, cross-sectional analysis of baseline
data from a controlled clinical trial [MOBIL-study (Mor-
bid Obesity treatment, Bariatric surgery versus Intensive
Lifestyle intervention Study) (ClinicalTrials.gov number
NCT00273104)] [21]. The study design and setting have
previously been described in detail [22]. A brief sum-
mary of materials and methods is given below.
Setting/Participants
All participants were recruited from the Morbid Obesity
Centre, Vestfold Hospital Trust, Tønsberg, Norway. The
study protocol had the approval of the regional ethics
committee and all patients provided written informed
consent. Only patients with extreme obesity (obesity
grade III; BMI ≥ 40 kg/m²) were included in the present
study. Of the 181 patients screened for participation in
the MOBIL-study [21], 35 patients were excluded due to
a BMI < 40 kg/m² (n = 32) or a missing oral glucose
tolerance test (OGTT; n = 3). After the exclusion of an
additional nine patients who failed to comply with sleep
registrations, 137 extremely obese patients (101 females)
were included in the present analysis (figure 1).
Variables and definitions
The primary outcome variable was OSA, which was
defined as at least five apneas or hypopneas, lasting
more than ten seconds, per hour. The main explanatory
variable was glucose tolerance (categorised as normal
glucose tolerance (NGT), preDM and T2DM) according
to the American Diabetes Association classificiation
2010 [23]). Other explanatory variables and possible
confounders were age, gender, anthropometric mea-
sures, smoking, alcohol consumption, hypertension, rele-







for inclusion  
BMI<35 kg/m² (n=3)  
Failed registrations (n=9)  
BMI 35-40 kg/m² (n=29) 
Missing OGTT (n=3)  
Figure 1 Flow chart of 181 patients screened for participation
in the MOBIL-study. Initially three patients were excluded due to a
BMI < 35 kg/m² and nine due to failed sleep registrations. Twenty
nine of these patients had a BMI < 40 kg/m² and three had a
missing OGTT, thereby leaving 137 extremely obese patients for
inclusion in the present analysis.
Fredheim et al. Cardiovascular Diabetology 2011, 10:84
http://www.cardiab.com/content/10/1/84
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HOMA-IR) and high sensitivity CRP (hsCRP). Arterial
hypertension was defined by systolic blood pressure ≥
140 mmHg, diastolic blood pressure ≥ 90 or the use of
antihypertensive medication. Microalbuminuria was
defined as albumin-creatinine ratio ≥ 3 mg/mmol and <
30 mg/mmol, and manifest proteinurea as albumin-crea-
tinine ratio ≥30 mg/mmol.
A computer based homeostasis model assessment of
insulin resistance (HOMA-IR) was used, HOMA Calcu-
lator v2.2.2 [24].
An apnea was defined as a 90% or more reduction of
baseline nasal air flow lasting at least ten seconds. Hypop-
neas were defined as a 50% - 90% decrease in pre-event
baseline of nasal air flow lasting ≥ 10 seconds accompa-
nied by at least a 3% drop in oxygen saturation and/or
signs of awakening or increased stress. OSA was defined
as having an apnea-hypopnea index (AHI) ≥ 5 events/
hour. Mild OSA was defined as AHI 5-15, moderate 15-30
and severe 30 or more events/hour. Scoring rules were in
accordance with the American Academy of Sleep Medi-
cine manual for scoring of sleep from 2007 [25].
Data sources/measurement
The reference standard method of sleep registration is
polysomnography, whereby patients are admitted and
monitored during an entire night’s sleep. This method
is, however, both time consuming and expensive, and
removes the patient from his/her natural sleep environ-
ment. Portable monitors, on the other hand, can be
used at home and are simple to function. This enables
the patient to maintain normal sleep environment and
pre-bed rituals [26]. The accuracy of home sleep diag-
nostic systems like the Embletta™ is considered to be
sufficient for most patients in the diagnosis of OSA
[27,28]. The night to night variability of sleep-disordered
breathing is low, and a retrospective study performed by
Stepnowsky et al suggests that one nights recording is
sufficient to diagnose OSA in nine out of ten cases [29].
The sleep registrations were performed using Emble-
tta™, a portable multi-channel recorder consisting of a
nasal cannula, two piezoelectric belts, a finger pulse oxi-
meter and a body position detector [28]. The two piezo-
electric belts were placed around the thorax and
abdomen to monitor respiratory movements. To avoid
inter-rater variation, Embletta™ recordings were manu-
ally scored by the same person [30]. In a study of a large
dataset the mean epoch by epoch agreement between
scorers for all records was 73% (range 67-82%) [31].
The equipment assembly included both written and
oral instructions. The patients equipped themselves
prior to going to bed and the registrations were scored
the next day. Treatment was provided according to cur-
rent guidelines [32]. Patients using continuous positive
airway pressure prior to the study had a one week
wash-out period during which they did not use the
machine. All patient data was registered in a Case
Report Form (CRF).
All patients, except those with drug-treated T2DM,
underwent a standardised OGTT [33]. The patients were
categorised into three groups: NGT; fasting plasma glu-
cose <5.6 mmol/L and/or 2-hour plasma glucose <7.8
mmol/L, preDM; fasting plasma glucose 5.6 - 6.9 mmol/L
and/or 2-hour plasma glucose 7.8 - 11.0 mmol/l or
T2DM; fasting plasma glucose ≥ 7.0 mmol/L or 2-hour
plasma glucose ≥ 11.1 mmol/L. In addition, patients with
either preDM or T2DM were categorised as to their hav-
ing abnormal glucose tolerance in supplementary analyses.
Statistical methods
Data are given as either mean (SD) or proportions (%)
unless stated otherwise. Between group differences were
assessed using independent samples t-test or analysis of
variance (ANOVA) (continuous data) and Fisher’s exact
test (categorical data). Skewed variables were transformed
using natural logarithms before statistical analysis. Multi-
ple logistic regression analyses with pre-defined explana-
tory variables and OSA (yes/no, cut off AHI = 5) as the
dependent variable were also performed [25]. We fitted
one crude (unadjusted) logistic regression model (model
1) and three separate multiple logistic regression models
(models 2-4). In model 1 glucose tolerance status as a
categorical variable was entered as the sole explanatory
variable. In model 2 we adjusted for established confound-
ing factors; gender, age and BMI (waist circumference,
neck circumference and waist-to-hip ratio were substi-
tuted for BMI in supplementary analyses). In model 3
HOMA-IR was added to model 2 to address the possible
modifying effect of insulin resistance. In model 4, in order
to assess the possible impact of inflammation, hsCRP was
added to model 3. In supplementary analyses glucose tol-
erance as a categorical variable was replaced with HbA1c.
The multiple logistic regression analysis was repeated in
all models using AHI cut off 15: the recommended clinical
cut off for initializing CPAP treatment [32].
To address the issue of multicollinearity we performed
calculations of Spearman correlation between categories
of glucose tolerance and both HOMA-IR and hsCRP. In
addition we assessed the variance inflation factor (VIF)
in the logistic regression models. The analyses were per-
formed using SPSS 16.0 (SPSS, Chicago, IL).
Results
A total of 42 (31%) patients had mild OSA, 18 (13%)
moderate OSA, and 24 (18%) severe OSA. The preva-
lence of OSA was higher in men (81%) than in women
(55%), p = 0.006, with the severity of OSA more pro-
nounced in males than in females, chi square test p <
0.001 (figure 2). In addition, the prevalence of OSA was
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significantly higher among postmenopausal (26 out of
29, 90%) than premenopausal women (29 out of 72,
40%), p < 0.001.
Demographic, clinical and biochemical characteristics
of the 137 extremely obese subjects, according to the
presence or absence of OSA, are shown in table 1.
Patients with OSA were significantly older, and they had
longer neck circumference, higher waist-to-hip ratios
and a higher prevalence of comorbid conditions than
those without OSA. There were no significant differ-
ences between groups regarding smoking and alcohol
consumption (table 1).
The prevalence of albuminuria was higher in the OSA
group than in the non-OSA group. Mean serum leptin
was significantly lower in the OSA than in the non-OSA
group, while other measures of inflammation did not
differ significantly between groups.
The prescription of analgesics, psychofarmacological
drugs, antidepressants, sleep medications and medica-
tion for asthma or chronic pulmonary disease did not
differ between groups (data not shown). In contrast, the
proportion of patients using antihypertensive drugs was
higher in the OSA-group (34%) than in the non-OSA
group (13%), p = 0.009.
Sleep registration data and measures of glucose metabo-
lism of the 137 extremely obese are presented in table 2.
Fasting serum glucose, post-challenge serum glucose and
HbA1c were significantly higher in the OSA group than
in the non-OSA group. There was no significant
difference between the two groups regarding s-insulin and
HOMA-IR.
OSA according to category of glucose tolerance
A total of 39 (29%) subjects had NGT, 58 (42%) preDM
and 40 (29%) T2DM. Among the patients with NGT
33% had OSA, while 67% of the preDM patients and
78% of the T2DM patients had OSA, p = 0.001 and p <
0.001, respectively. The distribution of glucose tolerance
categories among different OSA severity categories is
shown in table 3.
The proportion of patients with OSA was significantly
higher in female patients with preDM or T2DM than in
those with NGT, p = 0.004 and p < 0.001, respectively
(figure 3). These differences were particularly pro-
nounced in premenopausal women (figure 4).
BMI did not differ significantly between the various
glucose tolerance groups: NGT-group mean BMI (SD)
46.5 (4.7) kg/m², preDM-group 47.9 (6.8) kg/m² and the
T2DM-group 45.9 (4.8) kg/m², p = 0.220. In contrast,
mean age increased with worsening glucose tolerance:
NGT-group 39 (11) years, preDM-group 43 (10) years
and T2DM-group 46 (5) years, respectively, p < 0.001.
Association between OSA and various measures of
glucose tolerance
In a crude, unadjusted logistic regression model (model
1) subjects with preDM and T2DM had approximately
4- and 6-fold increased odds of OSA compared with the
normoglycemic group (Table 4). The odds of OSA in
preDM and T2DM were attenuated after adjustment for
gender, age and BMI (model 2), but remained statisti-
cally significant. The substitution of BMI with other
anthropometric measures in model 2 did not signifi-
cantly change the association between abnormal glucose
tolerance and OSA (data not shown). Finally, both
preDM and T2DM remained associated with signifi-
cantly higher odds of OSA after further adjustments for
HOMA-IR and high sensitive CRP (model 4). Gender
and age were both strong predictors of having OSA
with ORs (95% CI) of 4.2 (1.2, 14.4) and 1.15 (1.08,
1.21), respectively.
As an addition to model 4 we adjusted for smoking,
alcohol consumption, OSA relevant medication (benzo-
diazepines, tricyclic antidepressants and antipsychotics)
and hypertension (systolic and diastolic), with none of
these significantly altering the OR of having OSA (data
not shown). After replacing AHI cut off 5 (events/hour)
with AHI cut off 15 as the dependent variable in the
model, glucose tolerance was not significantly associated
with AHI ≥ 15.
We tested for correlations between HOMA-IR, hsCRP
and glucose tolerance using Spearmans correlation coef-
ficient. HOMA-IR and glucose tolerance had a correla-
tion coefficient of 0.33, p < 0.001. This means a
moderate correlation between HOMA and glucose toler-
ance status, with variation in HOMA-IR explaining 11%
of the variation in glucose tolerance. Thus we can safely
adjust for HOMA-IR in the logistic regression model.
HsCRP and glucose tolerance had a correlation coeffi-
cient of 0.03, p = 0.698
Figure 2 Categories of morbidly obese subjects according to
various levels of the apnea-hypopnea index (AHI). Dotted bars
represent patients without OSA (AHI < 5 events/hour). Mild OSA is
defined as AHI 5 - 15 events/hour, moderate OSA as 15 - 30 events/
hour and severe OSA as > 30 events/hour.
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PreDM and T2DM were assembled in one group;
abnormal glucose tolerance; and replaced with the glu-
cose tolerance categories in the multiple logistic regres-
sion model. In model 4 subjects with abnormal glucose
tolerance had an OR (95% CI) of having OSA of 4.4
(1.4, 13.8).
Glucose tolerance as a categorical variable was
replaced with HbA1c in supplementary logistic regres-
sion analyses. HbA1c was not significantly associated
with OSA in these models, odds ratio (95% CI) 1.29
(0.79, 2.12, p = 0.314).
Discussion
This study demonstrates that extremely obese patients
with type 2 diabetes and prediabetes have higher odds
of OSA, even after adjustment for age, gender, overall
obesity (BMI), insulin resistance, inflammation, hyper-
tension, smoking, alcohol consumption and medication.
Interpretation
That OSA may cause or worsen glucose tolerance has
been firmly established over the last few years
[7,17-20,34,35]. Our main objective was, however, to
explore the reverse relationship by examining whether
extremely obese subjects with abnormal glucose toler-
ance (preDM or T2DM) had higher odds of OSA. In
accordance with Foster et al, we have demonstrated a
particularly high prevalence of OSA among severely
obese patients with T2DM (78% in our study as com-
pared to 86% in the Foster study) [34]. We extend these
Table 1 Anthropometric data and comorbidities in 137 extremely obese subjects according to presence or absence of
obstructive sleep apnea
Variables All participants OSA no OSA yes p-value
N 137 53 (39%) 84 (61%)
Gender (male/female) 36/101 (26/74%) 7/46 (19/45%) 29/55 (81/55%) 0.006
Age (years) 43 (11) 36 (8.8) 48 (9.8) <0.001
Smokers 36 (26%) 15 (28%) 21 (25%) 0.830
Alcohol consumption (units/week) 1.1 (1.8) 0.9 (1.5) 1.2 (2.1) 0.350
Anthropometric measures
BMI (kg/m²) 46.9 (5.7) 46.3 (5.2) 47.2 (6.1) 0.377
Weight (kg) 136 (22.2) 134 (22.3) 137 (22.1) 0.324
Neck (cm) 42 (4.2) 40.5 (3.8) 43.1 (4.1) <0.001
Waist (cm) 135 (14) 132 (13.6) 136 (13.5) 0.097
Hip (cm) 139 (12) 140 (10.0) 138 (13.2) 0.389
Waist-to-hip ratio 0.98 (0.09) 0.9 (0.1) 1.0 (0.1) 0.005
Blood pressure (mean value, 24-hour ambulatory pressure)
Systolic (mmHg) 135 (17) 128 (14) 139 (18) <0.001
Diastolic(mmHg) 84 (10) 81 (10) 86 (10) 0.016
Comorbidities
Coronary heart disease 5 (4%) 0 (0%) 5 (6%) 0.156
Hypertension 48 (35%) 10 (19%) 38 (45%) 0.002
Albuminuria
Microalbuminuria 19 (14%) 4 (8%) 15 (19%) 0.126
Macroalbuminuria 4 (3%) 0 (0%) 4 (5%) 0.153
Hypothyreosis 18 (13%) 6 (11%) 12 (14%) 0.796
Anxiety and/or depression 56 (41%) 28 (53%) 28 (33%) 0.032
Asthma 35 (26%) 16 (30%) 19 (23%) 0.421
Chronic obstructive pulmonary disease 5 (4%) 2 (4%) 3 (4%) 1.000
Inflammation
Leptin (microg/l) 60.9 (19.3) 66.6 (16.4) 57.4 (20.3) 0.001
Visfatin (ng/ml) 26.0 (63.2) 33.2 (97.6) 21.5 (23) 0.692
High sensitive CRP (mg/l) 3.0 (2.6) 3.5 (3.2) 2.6 (2.1) 0.231
Osteoprotegerin (microg/ml)( 2644 (1640) 2381 (1413) 2809 (1757) 0.099
Adiponectin (pg/ml) 5510 (3368) 5278 (2633) 5656 (3767) 0.954
IL1Ra (pg/ml) 964 (1964) 877 (1913) 1020 (2004) 0.396
Leptin:adiponectin ratio (ng/ml:pg/ml) 0.016 (0.012) 0.017 (0.012) 0.015 (0.012) 0.096
Variables are given as either mean (SD) or proportions (%). Statistical analysis: Fisher’s exact test (categorical data), independent samples t-test (continuous data)
and Mann-Whitney U test (non-parametric, continuous data).
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findings by showing that whilst 2 out of 3 obese patients
with preDM had OSA, only 1 out of 3 patients with
NGT had OSA. Interestingly, the relationship between
glucose tolerance category and OSA was particularly
pronounced in premenopausal subjects (figure 4). While
less than 20% of the premenopausal patients with NGT
had OSA, more than half the patients with abnormal
glucose tolerance had OSA. This finding might be a
result of the redistribution of adipose tissue to more
central parts of the body caused by the hormonal
changes during menopause [36]. In older males the pre-
valence and severity of OSA might decrease because of
redistribution of body fat from the central to the periph-
eral depots. This is possibly a result of lower testoster-
one levels. Taking into account the very high prevalence
of OSA across glucose categories among morbidly obese
men and postmenopausal women, the power of the pre-
sent study is insufficient to reveal any possible differ-
ences between glucose categories. In our study less than
one third of patients (29%) had NGT, while 42% suf-
fered from preDM. Two out of three patients with
preDM had concomitant OSA. In the light of these fig-
ures a considerable proportion of extremely obese sub-
jects could suffer from unrecognized OSA.
The relationship between abnormal glucose tolerance
(preDM/T2DM) and OSA might have several explana-
tions. First, it is well established that OSA is associated
with insulin resistance and high insulin levels [37]. A
causal relationship between these conditions remains,
however, to be established [38].
As subjects with abnormal glucose tolerance often
have high insulin levels, our results are indirectly sup-
ported by a prospective study which demonstrated that
high insulin levels were associated with higher incidence
of sleep apnea [17]. In women with polycystic ovary syn-
drome (PCOS) insulin resistance is the strongest predic-
tor of OSA [39]. As insulin resistance seems to be the
primary defect in these patients, this could support our
findings of an association between preDM, T2DM and
OSA. One possible mechanism for these observations
may be that the inflammation associated with hyperin-
sulinemia, insulin resistance and visceral adiposity
induces OSA [40]. Inflammation of the upper airways
(UA) contributes to narrowing the lumen and thus
increases the obstructive tendency.
Although the patients with preDM and T2DM had
higher HOMA-IR than those with NGT, adjustments
for HOMA-IR did not substantially alter the relationship
between glucose tolerance category and OSA. This sug-
gests that insulin resistance cannot explain the relation-
ship between glucose intolerance and OSA in our study.
On average the patients with OSA had significantly
lower levels of leptin than those without OSA (table 1).
As men generally tend to have lower leptin levels than
Table 2 Sleep registration data and glucose metabolism characteristics in 137 extremely obese subjects according to
the presence or absence of obstructive sleep apnea (OSA)
Variables All participants OSA no OSA yes p-value
N 137 53 (39%) 84 (61%)
Sleep registration
Apnea-Hypopnea index 16 (20) 2 (2) 25 (22) <0.001
Oxygen desaturation index 17 (18) 3 (3) 26 (21) <0.001
Snoring (5 of sleep time) 19 (21) 11 (14) 23 (23) <0.001
SpO2 (%) 93 (3) 95 (2) 93 (3) <0.001
Glucose metabolism
Glucose, fasting (mmol/l) 6.6 (2.0) 5.8 (1.1) 7.1 (2.3) <0.001
Glucose, 2 hour (mmol/l) 7.6 (3.2) 6.5 (2.5) 8.3 (3.4) 0.001
HbA1 (%) 5.9 (1.1) 5.5 (0.8) 6.1 (1.2) 0.001
Insulin (pmol/l) 201 (89) 193 (78) 207 (96) 0.468
HOMA Insulin Resistance 3.8 (1.7) 3.6 (1.4) 4.0 (1.8) 0.178
Variables are given as either mean (SD) or proportions (%). Statistical analysis: Fisher’s exact test (categorical data) and independent samples t-test (continuous
data).
Table 3 Prevalence of various categories of glucose tolerance according to the presence and severity of obstructive
sleep apnea in 137 extremely obese subjects








Normal glucose tolerance 49% (26) 10% (4) 17% (3) 25% (6)
Prediabetes 34% (18) 52% (22) 50% (9) 38% (9)
Type 2-diabetes 17% (9) 38% (16) 33% (6) 38% (9)
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women, the high proportion of men with OSA might
partly explain this difference [41]. There was, however,
no gender significant difference between the patients
with or without OSA in terms of their leptin levels (data
not shown). It cannot be ruled out that this is due to a
type-II error, encountered because of the low frequency
of males without OSA (n = 7).
Our finding of an apparently inverse relationship
between leptin and OSA is still to be explored. Some
previous studies found a positive correlation between
leptin levels and OSA [42,43], whilst others have sug-
gested that the apparent association between OSA and
leptin levels is explained by higher BMI [6,11]. By con-
trast, in our study body weight did not differ signifi-
cantly between patients with or without OSA.
The pathophysiology of OSA is multi-factorial, the
most obvious factor being obesity which is associated
with the physical narrowing of the airways. Both adipose
tissue and diabetes are known to produce inflammation.
Increased mucosal thickness, secondary to general
inflammation, may contribute to airway narrowing and
collapse. Moreover, diabetic autonomic neuropathy can
be a functional factor in OSA by reducing the effective-
ness of the UA dilator muscles [15]. This theory is
strengthened by the fact that respiratory disturbances
are more frequent during rapid eye movement (REM)
sleep when the tone of the UA dilator muscles is
reduced. The autonomic contribution to maintaining a
patent airway is therefore substantial. Accordingly, dia-
betes could increase the risk of developing OSA via two
mechanisms; by inflammation and by impairment of the
autonomic nervous system controlling the UA dilator
muscles. As well as being a risk factor for OSA, visceral
obesity plays an important role in the development of
T2DM by mobilizing free fatty acids and inflammatory
cytokines, both of which promote insulin resistance [44].
Strengths and limitations
The strengths of the present study include the relatively
high number of extremely obese subjects with a high
prevalence of abnormal glucose tolerance and OSA,
thereby combining three profoundly intercorrelated
medical conditions. The method used to categorise sleep
apnea has been validated in several studies. There are
some limitations to this study, the main being the cross-
Figure 3 Prevalence of OSA in 137 extremely obese subjects
(101 females) according to various categories of glucose
tolerance.
Figure 4 Prevalence of OSA in 137 extremely obese subjects
(101 females) according to various categories of glucose
tolerance. Females are subgrouped according to menopausal
status. The mean (SD) ages of men, premenopausal- and
postmenopausal women were 44 (11), 38 (8) and 57 (7) years,
respectively.










Prediabetes 4.4 (1.9-10.6) a 3.3 (1.1-9.4) c 3.2 (1.0-10.1) c 4.0 (1.2-13.2) c
Type 2-diabetes 6.9 (2.5-18.7) a 4.3 (1.3-14.7) c 4.3 (1.2-16.4) c 5.4 (1.3-21.5) c
Gender 5.3 (1.7-17.1) b 5.0 (1.5-16.5) b 4.2 (1.2-14.4) c
Age 1.15 (1.08-1.21) a 1.15 (1.08-1.22) a 1.15 (1.08-1.21) a
BMI 1.05 (0.97-1.14) 1.05 (0.97-1.14) 1.08 (0.99-1.18)
HOMA-IR 1.0 (0.8-1.3) 0.9 (0.7-1.3)
hsCRP 0.9 (0.7-1.0)
a p ≤ 0.001 b p ≤ 0.01 c p < 0.05
Data are given as odds ratio (95% CI) using multiple logistic regression analysis.
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sectional study design which eliminates the ability to
determine causality. The study includes mainly Cauca-
sians, and as such the findings might not be generaliz-
able to other populations. Our subjects are extremely
obese and our results are therefore not directly applic-
able to less obese or normal weight subjects.
Finally, portable unattended sleep polygraphy was used
to give sleep registrations: when compared to full poly-
somnography this monitor does not give information
about sleep stages and thus cannot differentiate between
REM and NREM OSA. Exact sleep time was thus not
registered through an EEG, and time in bed was used to
estimate sleep time.
Conclusion/clinical implications
In the present study we have shown that preDM and
T2DM are commonly observed and associated with
OSA in extremely obese subjects. Our findings support
the recommendations from the International Diabetes
Federation (IDF) suggesting that subjects with T2DM
should be screened for OSA [7]. If the relationship
between preDM and OSA is verified by others, this may
indicate that obese subjects with preDM should also be
screened for OSA.
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